AGT and type 2 diabetes mellitus: The impact of two ARBs (irbesartan and losartan) on the development of DN in patients with T2DM, overt proteinuria, and renal dysfunction was examined in the IDNT (Irbesartan Diabetic Nephropathy Trial) and RENAAL (The Reduction in End Points in NIDDM with the Angiotensin II Antagonist Losartan) studies (Table 2).